BiomX Inc.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 19, 2026
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Stockholders’ Equity (Deficit) (unaudited)
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
(U.S, dollars in thousands, except share and per share data)
| Series Y Redeemable Convertible Preferred Shares · Series X Redeemable Convertible Preferred Shares · Common stock · Additional · Accumulated Other · Receivables · Non- · Total stockholders’ | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of shares | Amount | Number of shares | Amount | Number of shares | Amount | paid-in capital | Comprehensive Income (Loss) | Accumulated deficit | on account of shares | Controlling interests | equity (deficit) | |
| BALANCE AT DECEMBER 31, 2025 | - | - | 147,512 | 18,617 | 1,593,703 | 7 | 196,970 | - | (216,896) | - | - | (1,302) |
| - | ||||||||||||
| Issuance of Series Y Convertible Preferred Stock | 3,300 | - | - | - | - | - | - | - | - | - | - | - |
| Preferred dividends on Series Y Convertible Preferred Stock | - | 85 | - | - | - | - | (85) | - | - | - | - | - |
| Conversion of Series Y Convertible Preferred Stock into common stock | (3,300) | (85) | - | - | 1,650,000 | * | 85 | - | - | - | - | - |
| Exercise of warrants into common stock | - | - | - | - | 3,300,000 | * | 16,785 | - | - | (3,300) | - | 13,485 |
| Reclassification of embedded conversion derivative upon conversion of Series Y Convertible Preferred Stock | - | - | - | - | - | - | 7,818 | - | - | - | - | 7,818 |
| Share based compensation | - | - | - | - | - | - | (1,742) | - | - | - | - | (1,742) |
| Comprehensive loss for the period | - | - | - | - | - | - | - | - | (19,140) | - | - | (19,140) |
| BALANCE AT MARCH 31, 2026 | - | - | 147,512 | 18,617 | 6,543,703 | 7 | 219,831 | - | (236,036) | (3,300) | - | (881) |
| Share based compensation | - | - | 1,380,000 | 1 | 3,987 | - | - | - | - | 3,988 | ||
| Issuance of shares for investment in Zorronet | - | - | 1,300,000 | * | 3,757 | - | - | - | - | 3,757 | ||
| Issuance of warrants and shares for investment in DFSL | - | - | 923,000 | * | 4,124 | - | - | - | - | 4,124 | ||
| Issuance of shares as partial payment of promissory note | - | - | 1,013,637 | * | 379 | - | - | - | - | 379 | ||
| Issuance of Common Stock under At the Market Sales Agreement, net of $ 39 issuance costs | - | - | 793,005 | * | 291 | - | - | - | - | 291 | ||
| Offset of promissory note | - | - | - | 3,000 | - | 3,000 | ||||||
| Subsidiaries consolidation for the first time | - | - | - | 6,818 | 6,818 | |||||||
| Foreign currency translation adjustments | - | - | (21) | 14 | (7) | |||||||
| Conversion of A&R Warrants | - | - | 132,484 | * | * | - | - | |||||
| Conversion of Series X Redeemable Convertible Preferred Shares | - | - | (95,914) | (12,105) | 504,812 | * | 12,105 | - | ||||
| Loss for the period ended June 30, 2026 | - | - | - | - | - | - | - | (3,772) | - | (74) | (3,846) | |
| BALANCE AT JUNE 30, 2026 | - | - | 51,598 | 6,512 | 12,590,641 | 8 | 244,474 | (21) | (239,808) | (300) | 6,758 | 17,623 |
| (*) | Less than $1. |
|---|
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (continued)
(U.S, dollars in thousands, except share and per share data)
| Redeemable Convertible Preferred Shares · Common stock · Additional · Total Stockholder’ | |||||||
|---|---|---|---|---|---|---|---|
| Number of shares | Amount | Number of shares (**) | Amount | paid-in capital | Accumulated deficit | equity (capital deficiency) | |
| BALANCE AT DECEMBER 31, 2024 | 147,735 | 18,645 | 18,176,661 | 6 | 186,194 | (180,697) | 24,148 |
| Issuance of Common Stock, Registered Pre- Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs | - | - | 2,828,283 | * | 878 | - | 878 |
| Issuance of Common Stock under Inducement Letter Agreements | - | - | 3,961,109 | 1 | 6,472 | 6,473 | |
| Stock-based compensation expenses | - | - | 659 | 659 | |||
| Net loss | - | - | (7,659) | (7,659) | |||
| BALANCE AT MARCH 31, 2025 | 147,735 | 18,645 | 24,966,053 | 7 | 194,203 | (188,356) | 24,499 |
| Exercise of Private Pre-Funded Warrants and Common Warrants | 1,202,314 | * | 2 | 2 | |||
| Issuance of Common Stock upon restricted stock units vesting | 274,890 | * | * | ||||
| Stock-based compensation expenses | 696 | 696 | |||||
| Net loss | (6,037) | (6,037) | |||||
| BALANCE AT JUNE 30, 2025 | 147,735 | 18,645 | 26,443,257 | 7 | 194,901 | (194,393) | 19,160 |
| (*) | Less than $1. |
|---|---|
| (**) | All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 8. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.